CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cipla's Board of Directors met on May 13, 2026 and approved several items. The main item under this filing is the appointment of M/s Joshi Apte & Associates, Cost Accountants (Firm Registration no. 000240) as Cost Auditors of the Company for FY 2026-27. Additionally, the Board approved stock option grants of 1,76,389 options and ESARs of 5,96,244 units to employees under existing ESOS schemes, with exercise prices of INR 2 per option/share. The Board also appointed Mr Sushrut Kulkarni as President & Global Chief – Integrated Product Development (IPD), effective May 18, 2026. He is a veteran from Dr Reddy's Laboratories and will be part of Cipla's Management Council.
The appointment of M/s Joshi Apte & Associates as Cost Auditors is a routine governance requirement and has no direct impact on shareholding or stock price. The stock option grants represent employee compensation costs that may have marginal dilution impact.